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AbstrACt
Introduction Intravenous fluid therapy during 
gastrointestinal surgery is a life-saving part of 
the perioperative care. Too little fluid may lead to 
hypovolaemia, decreased organ perfusion and circulatory 
shock. Excessive fluid administration increases 
postoperative complications, worsens pulmonary and 
cardiac function as well as the healing of surgical wounds. 
Intraoperative individualised goal-directed fluid therapy 
(GDT) and zero-balance therapy (weight adjusted) has 
shown to reduce postoperative complications in elective 
surgery, but studies in urgent gastrointestinal surgery 
are sparse. The aim of the trial is to test whether zero-
balance GDT reduces postoperative mortality and major 
complications following urgent surgery for obstructive 
bowel disease or perforation of the gastrointestinal tract 
compared with a protocolled standard of care.
Methods/analysis This study is a multicentre, randomised 
controlled trial with planned inclusion of 310 patients. 
The randomisation procedure is stratified by hospital 
and by obstructive bowel disease and perforation of the 
gastrointestinal tract. Patients are allocated into either ‘the 
standard group’ or ‘the zero-balance GDT group’. The latter 
receive intraoperative GDT (guided by a stroke volume 
algorithm) and postoperative zero-balance fluid therapy based 
on body weight and fluid charts. The protocolled treatment 
continues until free oral intake or the seventh postoperative 
day. The primary composite outcome is death, unplanned 
reoperations, life-threatening thromboembolic and bleeding 
complications, a need for mechanical ventilation or dialysis. 
Secondary outcomes are additional complications, length of 
hospital stay, length of stay in the intensive care unit, length 
of mechanical ventilation, readmissions and time to death. 
Follow-up is 90 days. We plan intention-to-treat analysis of 
the primary outcome.
Ethics and dissemination The Danish Scientific Ethics 
Committee approved the GAS-ART trial before patient 
enrolment (J: SJ-436). Enrolment of patients began in 
August 2015 and is proceeding. We expect to publish the 
GAS-ART results in Summer 2019.
trial registration number EudraCT 2015-000563-14.
IntroduCtIon  
Death and complications are frequent 
following urgent major gastrointestinal 
surgery.1 Mortality rates are 15% to 25%,2–4 
and the morbidity is ominous with compli-
cation rates reported for more than 50% of 
the patients.5 Approximately 4500 patients 
annually undergo urgent gastrointestinal 
surgery in Denmark and several hundred of 
thousand people around the globe.6 7 Intra-
venous fluid administration is a life-saving 
part of the perioperative treatment. The 
challenge is to determine the right volume 
of fluid to be given. Within planned gastro-
intestinal surgery, the fluid volume given 
has noticeably influenced the postoperative 
outcome.8–13 However, trials testing periop-
erative fluid therapy for patients undergoing 
urgent surgery are sparse.
Intravenous fluid administration is neces-
sary for upholding circulation and securing 
oxygen delivery to vital organs. Patients 
suffering from conditions requiring an 
urgent surgical intervention are frequently 
impaired by compromised fluid intake, 
nausea, vomiting, sepsis and other patho-
logical fluid losses highlighting the vital 
strengths and limitations of this study
 ► This is a randomised controlled multicentre trial 
testing the effect of goal-directed fluid therapy in 
urgent gastrointestinal surgery.
 ► The multicentre design and an easy identification of 
the patient group supports broad clinical implemen-
tation of the study results.
 ► The primary outcome is clearly defined, clinically 
relevant and applies to the patients.
 ► Protocol adherence is secured by prelaminar and 
continuous teaching combined with regular assess-
ment by the ‘units of Good Clinical Practice’, an inde-
pendent data monitoring committee reinforcing the 
ICH-GCP (International Council for Harmonisation—
Good Clinical Practice) guideline.
 ► Despite a set-up that is not blinded, the primary out-
come will be assessor blinded.
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need for intravenous fluid therapy to prevent circulatory 
shock and death. Thus, liberal intravenous fluid admin-
istration in volumes far exceeding the losses before, 
during and after the surgical procedure is common prac-
tice.14 15 On the other hand, there is no reason to believe 
that the harmful effect of fluid overload seen in studies 
of elective surgical patients is not valid for the patients 
undergoing urgent surgery. Interstitial oedema aggra-
vate tissue inflammation, compromises wound healing 
and promotes anastomosis leakage.8 10 16 17 In addition, 
cardiac arrhythmia, pulmonary oedema and acute respi-
ratory distress syndrome may be the result.
The circulatory volume is difficult to measure or even 
estimate based on standard surveillance. Acute inflam-
mation and stress response affect heart rate (HR) and 
diuresis. Arterial blood pressure and central vein pressure 
(CVP) may react on severe hypovolaemia, but does not 
reliably estimate normovolaemia or fluid overload, that is, 
does not tell when to stop the intravenous fluid infusion. 
Accordingly, the common physiological parameters are 
incapable of guiding clinical fluid therapy. As the patients 
are often hypovolaemic at admission, a simple in–out fluid 
balance (as used in trials of elective surgery to avoid fluid 
overload) is not useful for the urgent surgical patients.
The call for a more dynamic variable has led to the use 
of stroke volume (SV) to guide the fluid administration, 
the so-called goal-directed fluid therapy (GDT). Aiming 
at a submaximal SV using bolus infusions of a colloid, 
GDT possesses the ability to avoid both hypovolaemia 
as well as excessive fluid administration. Studies, using 
intraoperative GDT in planned gastrointestinal surgery, 
have shown to reduce length of hospital stay and compli-
cations.12 13 18–21
The presented trial is testing whether an intervention 
using intraoperative GDT followed by a postoperative 
zero balance, named the ‘zero-balance GDT’ strategy (the 
GDT group), reduces postoperative mortality and major 
complications following urgent surgery of obstructive 
bowel disease or gastrointestinal perforation compared 
with a standard group (SDT group). The STD group 
follows an algorithm for fluid therapy used in the PULP 
trial (Peptic ULcer Perforation)22 resembling the fluid 
strategy used in River’s study of patients with sepsis.23 A 
fluid strategy, that to our knowledge is the best evidence-
based fluid algorithm used in the urgent setting. This 
treatment is based on mean arterial pressure (MAP), 
diuresis, HR, CVP and central venous oxygen saturation 
(SCV02). We suggest that zero-balance GDT may hold the 
ability to detect both hypovolaemia and fluid overload 
and guide the fluid therapy towards normovolaemia, 
thus reducing complications and death following urgent 
surgery.
The hypotheses are the following:
 ► Hypovolaemia as well as fluid overload compromises 
cardiac and pulmonary function prompting postop-
erative complications such as arrhythmia, myocardial 
infarcts, other thromboembolic events, pneumonia, 
pulmonary congestion, exudation in the pleural 
cavity, pulmonary oedema and acute respiratory 
distress syndrome.
 ► Hypovolaemia as well as fluid overload is harmful for 
the healing of tissues and surgical wounds, causing 
complications related to poor tissue healing and 
infection, that is, wound infections, wound rupture 
(superficial and deep), anastomosis leakage and sepa-
ration of a stoma from the skin.
MEthods And dEsIgn
The trial is a randomised, parallel group, open-label, 
multicentre, superiority trial. The primary outcome will 
be assessor blinded. The study protocol adheres to the 
SPIRIT (Standard Protocol Items: Recommendations 
for Interventional Trials) reporting guidelines.24 We 
launched the study at five public university hospitals from 
the three most Eastern regions in Denmark handling 
urgent surgery from 1.5 million inhabitants. In Denmark, 
public hospitals are free of charge and treat all patients in 
the need for urgent surgery.
Eligibility criteria
Anaesthesiologists and surgeons collaborate to carry out 
the trial. Selected trial anaesthetists are responsible for 
conducting the intraoperative GDT intervention.
Inclusion criteria
 ► The need for urgent gastrointestinal surgery due to 
radiologically verified gastrointestinal perforation or 
obstructive bowel disease.
 ► The presence of an anaesthetist qualified of 
conducting the intraoperative GDT intervention.
Exclusion criteria
 ► Surgery of palliative purposes and the dying patient 
(American Society of Anaesthesiologist (ASA) group 
5 to 6—ASA physical status classification).
 ► Major intra-abdominal surgery within the last 30 days.
 ► Iatrogenic gastrointestinal perforation.
 ► Dialysis on a regular basis.
 ► Patients unable to give informed consent for any 
reason.
 ► Age younger than 18 years.
 ► Pregnancy (positive urinary human chorionic 
gonadotropin).
Intervention
The patients are allocated to either (1) the GDT group or 
(2) the STD group. The treatment is initiated alongside 
the induction of the anaesthesia. Monitoring and data 
collection continue until the patient can drink and eat 
freely or to the seventh postoperative day.
In both groups, the treating physician administers 
preoperative antibiotics, antithrombotic and analgesia 
according to regional guidelines. The perioperative goals 
are MAP >65 mm Hg, HR <100 beats/min and SaO2 (arte-
rial oxygen saturation) >94%. Induction of anaesthesia is 
by propofol. Fentanyl and rocuronium are used if needed. 
Anaesthesia is by sevoflurane and fentanyl or propofol 
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and remifentanil. We allow local divergences. Additional 
epidural analgesia is used for laparotomy. We use inva-
sive blood pressure monitoring in both groups and will 
keep haemoglobin >70 g/L (4.3 mmol/L) (or >80 g/L 
(5.0 mmol/L) for patients with chronic ischaemic heart 
disease and >90 g/L (5.6 mmol/L) in case of acute isch-
aemic heart disease) using blood replacement therapy. 
Critical blood loss is treated with replacement of blood, 
plasma and platelets in the ratio 3:3:1. Intraoperatively, 
hourly diuresis is registered and arterial blood samples 
analysed.
In the GDT group, fluid optimisation follows the SV 
algorithm seen in figure 1, which ends when the patient 
leaves the operating room and proceeds as zero-balance 
approach. We use the FloTrac sensor and the EV1000 
monitor from Edwards Lifesciences. Before surgery, SV 
is measured and consecutive boluses of 3 mL/kg albumin 
5% are given until increase in SV is below 10%. Then, SV 
is measured every 15 minutes. The procedure is repeated 
if SV decreases >10%. Changes in SV following external 
factors, such as pneumoperitoneum, changes in body 
position, alternation in respirator settings or adminis-
tration of vasopressor or inotropic drugs, do not require 
fluid administration. Additional maintenance fluid 
replaces only pathological and physiological loses in the 
ratio 1:1, the latter amounting no more than 2 mL/kg/
hour including all intravenous medication (antibiotics, 
anaesthetics, etc). The aim is a zero-balance, limiting 
unnecessary interstitial fluid accumulation. Additional 
vasopressors are given to endeavour a MAP >65 mm Hg.
Postoperative fluid administration is adjusted according 
to the fluid chart and the postoperative body weight as a 
zero-balance approach. Furosemide is given if the accu-
mulated fluid balance exceeds 2 L or the body weight 
Figure 1 GDT regimen. Intraoperative fluid algorithm. GDT, goal-directed fluid therapy; i.v., intravenous; MAP, mean arterial 
pressure; SV, stroke volume.
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increases more than 2 kg. Prolonged intestinal paralysis 
might cause a net body weight gain of some kilograms 
and should not result in furosemide administration. 
Thus, clinical assessment alongside the data from fluid 
charts and body weight conditions the fluid replacement.
In the STD group, Ringers solution, saline 0.9% or 
albumin 5% are given intraoperatively to secure MAP 
>65 mm Hg and/or hourly diuresis >0.5 mL/kg/hour 
in accordance with the flowchart illustrated on figure 2. 
A central venous line is placed if the treating clinician 
finds it useful and CVP and SCV02 used to guide the fluid 
therapy. Vasopressors are used only if persistent hypoten-
sion (MAP <65 mm Hg) occurs.
Postoperative fluid therapy is given according to local 
routines aiming at acceptable MAP >65 mm Hg, HR <100/
min and diuresis >1 mL/kg/hour.
In both groups, postoperative analgesia is achieved with 
paracetamol, non-steroid anti-inflammatory drugs and/
or opioids according to guidelines, besides epidural anal-
gesia in case of laparotomy. Early mobilisation is endorsed 
by physiotherapist. Ventricular retention (failure to 
tolerate per oral intake) is treated with a gastric tube. 
Figure 2 STD regimen. Intraoperative fluid algorithm. CVP, central vein pressure; Hb, haemoglobin; MAP, mean arterial 
pressure; SCVO2, central venous oxygen saturation; STD, standard group.
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Metoclopramide or ondansetron is offered as antiemetic 
on demand.
The allocated treatment will be discontinued in all 
cases of a reoperation. The incidence will be registered as 
a part of the primary outcome. There is no other criteria 
for discontinuing the treatment in either group. Postop-
erative circulatory instability with a need for immediate 
care for example, septic shock is handled by the treating 
physician according to regional guidelines and over-
ruling the allocated treatment. However, when the urgent 
phase has ended, the treatment returns to the allocated 
regimen and the episode is registered as an outcome.
Overall protocol adherence is secured by the 
project anaesthetist intraoperatively and postoperatively 
by the local investigator at the surgical ward. Individually 
training of selected trial physicians at the surgical and 
aesthetic wards was completed before study initiation 
at each involved hospital to secure protocol adherence. 
Formal presentation of the study was given to all staff at 
the intensive care unit, surgical and anaesthetic wards. 
Pocket cards with flowcharts were distributed. During 
the study period, continuous education is given to nurses 
and physicians in the teams responsible for the urgent 
surgical patients.
We use a detailed monitoring plan to evaluate protocol 
compliance. Regular reviewing of intraoperative and 
postoperative treating-related data at each hospital is 
conducted by the project leader as well as an independent 
data monitoring committee ‘the unit of Good Clinical 
Practice’, which assesses all phases of the GAS-ART trial. 
For example, intraoperatively one initial dose of human 
albumin and less than 2 mL/kg/hour of maintenance 
fluid is expected in the GDT group and infusion of more 
than 2000 mL crystalloids in the STD group. Monitoring 
reports are acquired on a regular basis throughout the 
entire study period. Areas with potential protocol devia-
tions are corrected continuously.
Participant timeline
See figure 3 for the GAS-ART timeline.
Patient and public involvement
Patients or public were not involved in the development 
of the research question or outcome measures. Only 
medically trained physicians carry out the patient recruit-
ment and management in the study. A trial physician 
gives written and oral information on positive and nega-
tive aspects of the intervention to the patient. Simultane-
ously, information on the final study results is offered to 
all participating patients on request.
outCoME MEAsurEs
All outcome measures are registered 30 days postsurgical. 
The primary outcome is registered 90 days postsurgical. 
Table 1 lists the outcome measures.
Primary composite outcome
 ► All-cause mortality
 ► Unplanned reoperations
 – Any unplanned laparotomy or laparoscopy
 ► Life-threatening bleeding complications
 – For example, cerebral haemorrhage, disseminated 
intravascular coagulation or other bleeding lead-
ing to medical, surgical or endoscopic intervention
 ► Life-threatening thromboembolic events
 – For example, acute myocardial infarction, stroke, 
pulmonary or intestinal emboli/thrombosis.
 ► Respiratory insufficiency
 – Demanding mechanical respiratory support in-
cluding non-invasive ventilation
 ► Cardiac arrest (survived)
 ► Renal failure
 – Demanding dialysis
secondary outcome measures
The secondary outcome measures are minor complica-
tions different from the primary composite outcome and 
specified time spans.
 ► Minor complications: A complication with a need for 
medical or surgical treatment.
 ► Timespan in the operating room, at the recovery 
room, at the intensive care unit, with mechanical 
respiratory support and until death.
 ► Postoperative days with dialysis.
 ► Length of hospital stay.
sample size
Database inventory from Denmark shows a postopera-
tive mortality rate of 15.7% after acute colonic surgery 
and one of 18.2% after operation for perforated ulcer.4 25 
The most ill patients are incapable of giving informed 
consent, thus excluded. However, the frequency of major 
complications is expected to be high in the population. 
We estimated the combined incidence of overall death 
and major complications to be 25%. A previous study 
testing a similar intervention in elective major gastroin-
testinal surgery has shown a risk reduction of 50%8 and 
we estimated a reduction in the combined outcome to 
12.5%. We accepted a 5% risk of type 1 error and a power 
to detect a reduction of 80%. The calculated sample size 
was 149 patients in each group. The variance is unlikely to 
follow a normal distribution and the number of patients 
needed was adjusted to 155 in each group—a total of 310 
patients. We plan no interim analysis.
recruitment
Teams of dedicated trial physicians at each hospital 
screen all adult patients with a need for urgent gastroin-
testinal surgery according to the eligibility criteria. Verbal 
and written study information is given prior to surgery by 
the surgeon or anaesthetist and written informed consent 
is obtained before randomisation. With a planned inclu-
sion period of 2 to 3 years, we chose to initiate the trial 
in five hospitals. If the inclusion rate is unexpectedly 
low, additional physicians will be trained to perform the 
GDT intervention.
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Figure 3 Participant timeline. ASA, American Society of Anaesthesiologists; GAS-ART, GAstrointestinal Surgery Study protocol 
for A Randomised multicentre Trial; GDT, goal-directed fluid therapy; MAP, mean arterial pressure; STD, standard. 
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Table 1 Outcome measures
Complication Definition
Abdominal Superficial wound rupture Conservative or surgical treatment
Superficial wound haematoma Observed by a physician
Superficial wound infection Wound rupture, a need for removal of infected tissue or medical 
treatment
Wound infection and fascial defect A need for surgical cleavage or removal of infected tissue with 
fascial defect
Facial rupture Spontaneously fascial rupture
Anastomosis leakage Symptomatic and requiring treatment
Separation of stoma Cutaneous and subcutaneous defect
Re-perforation A need for relaparotomy
Peritonitis Debut intraoperatively or postoperatively
Intra-abdominal abscess Suspected radiologically with a need for medical or surgical 
treatment
Obstructive bowel disease A need for relaparotomy
Prolonged paralysis of intestine 7 days without flatus or faeces
Gastrointestinal bleeding A need for surgical or endoscopic treatment
Reoperation Other unplanned intra-abdominal reoperations
Infectious Sepsis Worsening postoperatively, debut intraoperatively or 
postoperatively. Graded according to sepsis-2 definitions43
Pneumonia Radiological documentation and one clinical sign: fever, 
leucocytosis, coughing or crepitus
Cystitis Symptomatic and documented bacteriuria
Other With a need for medical or surgical intervention
Cardiopulmonic Atrial arrhythmia Verified by ECG and a need for treatment
Ventricular arrhythmia Verified by ECG and a need for treatment
Acute myocardial infarction ECG pathology and elevated cardiac enzymes
Cardiac arrest Diagnosed by a physician with or without successfully 
resuscitation
Exudation to the pleural cavity Verified by radiology
Pulmonary congestion Suspected clinically with bilateral crepitus and positive effect of 
diuretic treatment
Pulmonary oedema Radiographic suspicion and a need for intensive care
Mechanical respiratory support A need for intubation or continuous non-invasive ventilation
Acute respiratory distress 
syndrome (ARDS)
ARDS according to the Berlin definition44
Other With a need for medical or surgical intervention
Thromboembolic Pulmonary embolism Verified by scintigraphy or CT scan
Deep venous thrombosis Verified by radiology
Other With a need for medical or surgical intervention
Renal Renal failure A need for dialysis
Other With a need for medical or surgical intervention
Central nervous 
system
Stroke or cerebral haemorrhage Neurological symptoms and relevant radiology or diagnosed by 
neurologist
Delirium/psychosis Deficiency in orientation, level of consciousness, cognition and/or 
psychosis
Other With a need for medical or surgical intervention
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AssIgnMEnt of IntErvEntIon
Allocation
We use a computer-generated block randomisation 
offered by OPEN-Randomise (Odense Patient data 
Explorative Network). We stratify by each hospital, and 
between obstructive bowel disease and perforation of 
the gastrointestinal tract. The study group of trial physi-
cians is given access to OPEN-Randomise by username 
and password. The allocation sequence is concealed 
for all members of the study group. Trial physicians 
document the randomisation identifier number and 
allocation in the patient record and the case report 
form.
blinding
The fluid therapy given in the GAS-ART trial includes 
the intraoperative and postoperative period at shifting 
departments involving many physicians and nurses. Addi-
tionally, clinical signs of hypovolaemia or hypervolaemia, 
for example, blood pressure, pulse, venous saturation, 
exudation to the pulmonic cavity, pulmonic oedema, 
subcutaneous oedema and diuresis are almost impossible 
to blind for the investigators. Thus, we could not find 
an effective way to blind the fluid therapy given in this 
trial. However, when the trial is completed, we conduct 
a blinded assessment of the primary outcome based on 
electronical patient records.
dAtA CollECtIon, MAnAgEMEnt And AnAlysIs
Intraoperative recording of fluid charts, blood pressure, 
HR and vasopressor use is collected by the trial physician. 
SV is recorded in the GDT group. In the postoperative 
phase, all enrolled patients are seen daily by a doctor on 
rounds who ensures protocol adherence. Data collection 
is in the electronical patient record, identified by the 
Danish personal registration number (CPR—det Centrale 
PersonRegister) including laboratory tests, radiology 
findings, microbiological results and other paraclinical 
results. Fluid charge and body weight are collected on 
paper forms. All patients will be Acute Physiology And 
Chronic Health Evaluation (APACHE II) scored the first 
day after surgery and patients admitted to the intensive 
care unit will be SOFA () scored daily. Follow-up is by the 
local investigator on postoperative days 30 and 90 either 
by telephone interview or by outpatient visit. Data transfer 
to the case report forms is secured only by the local inves-
tigator and trial physicians at each hospital to promote 
data quality and reviewed by the project leader. Addition-
ally, registration of the primary outcome will be done 
by two independent and blinded accessors reading the 
patient records from all participating patients, blinded 
for information on the given fluid therapy, body weight 
measurements and allocation.
Case report forms and patient records will be stored at 
Holbaek Hospital in a secured locker. A database on the 
safe network of Holbaek Hospital is used for data entry 
securing confidentiality and allowing range checks for 
data validation. The steering committee will have access 
to the final trial dataset. Trial physicians can apply for 
access to the database. Local investigators will have access 
to trial data at their respective hospital.
statistical methods and analysis
All data will be tested for normality and parametric statis-
tics used for normal distributed data, otherwise non-para-
metric statistics are used. χ2 test will be used for binominal 
data, Fischer’s exact test when expected values are below 
5. Risk will be calculated when relevant.
The primary composite outcome will be reported as 
‘intention to treat’. The result will be presented as an 
entity and separately for explorative reasons. If more 
than 20 patients are excluded after the randomisation, 
a ‘per-protocol’ analysis will be added. If baseline char-
acteristics are skewed, the effect will be assessed using a 
multiple logistic regression model and the adjusted as 
well as the unadjusted analysis of the primary outcome 
will be presented. If more than 10% of the intraopera-
tive data are missing, a worst-case and a best-case scenario 
will be presented. If the results are inconclusive, multiple 
imputations will be performed. Results will be presented 
two-tailed and a p-value<0.05 is considered significant.
The secondary outcomes will be analysed as ‘intention 
to treat’ and ‘per protocol’ if more than 20 patients are 
excluded after randomisation. Sequence for analysis is as 
follows: minor complications, specified time spans, physi-
ological data and finally data from blood samples.
Subsequently, subgroup analysis of the hypothesis 
presented in the Introduction section will be done. We 
plan analysis by centre and type of operation (laparo-
scopic vs laparotomy) to detect potential differences 
between hospitals and the two treatments. The incidence 
and severity of sepsis is likely to differ between patients 
with gastrointestinal perforation or obstructive bowel 
disease and data analysed separately focusing on number 
of organ failures. The results will highlight trends for 
further investigation as the number of participants is 
inconsequential.
dAtA MonItorIng
The GAS-ART trial will be conducted in adherence to 
International Council for Harmonisation—Good Clinical 
Practice (ICH-GCP) guidelines and the Declaration of 
Helsinki with data collection on paper case report forms. 
The GAS-ART trial is monitored by the independent units 
of Good Clinical Practice from Odense and Copenhagen 
securing an external monitoring of more than 10% of the 
completed case rapport forms and concordance with the 
ICH-GCP guidelines.
Four specified serious adverse reactions (SARs) as 
well as suspected unexpected serious adverse reac-
tions (SUSARs) will be reported according to regula-
tions from the unit of Good Clinical Practice and the 
Danish Health and Medicines Authority when suspected 
directly related to the infusion of saline, albumin or 
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Ringer’s solution: acute anaphylactic reaction, hyper-
natraemia (s-Na >155 mmol/L), central pontine myeli-
nolysis and seizures. The units hold the ability to abort 
the study if deemed necessary. The presence of SAR or 
SUSAR does not exclude the patient from the study since 
continuous fluid replacement therapy is unavoidable.
Patients withdrawing their consent are excluded 
from further intervention and data collection. Cases 
are expected to be few because the treatment and data 
collection rely on the healthcare professionals and devi-
ation from usual practice is of little inconvenience for 
the patient. Patients withdrawing their consent will be 
replaced. Due to safety regulations, any observed SAR 
and SUSAR will be registered for all included patients.
EthICs And dIssEMInAtIon
The trial was approved by the Danish Scientific Ethics 
Committee and the Danish Data Protection Agency 
(REG-18–2015) before patient enrolment. The study is 
classified as a drug trial by the Danish Medicines Agency 
(2014 12 13 19). The trial is registered at the European 
Clinical Trials Database.
We identify no additional risk for the patients enrolled 
in the GAS-ART trial compared with usual practice. Arte-
rial lines are generally used in patients with a need for 
urgent gastrointestinal surgery, and no additional inva-
sive procedures will be applied.
dissemination plan
We plan to publish study results in an international 
peer-reviewed journal. Negative as well as positive results 
will be published. Authors will have to meet the principles 
of the Vancouver Declaration.
The results will be presented at both national and inter-
national conferences of relevance. A letter will inform 
the participants about the study results when requested. 
Furthermore, the results will be presented at all involved 
hospitals and participating wards.
trial status
Patient inclusion was initiated in August 2015 at Holbaek 
University Hospital. The additional four centres were 
consecutively introduced. By February 2016, the five 
planned centres had begun patient inclusion. We expect 
that patient inclusion will increase as study algorithms 
gradually become integrated in the daily routines at each 
centre. On 23 February 2018, 243 patients were included.
dIsCussIon
The GAS-ART trial is a randomised clinical trial testing 
the effect of two distinct fluid regimens on postopera-
tive complications and death following urgent gastroin-
testinal surgery. Through the last 30 years, the effect of 
GDT optimisation has been tested on selected surgical 
patients, including high-risk patients. However, only a 
few studies have included emergency gastrointestinal 
surgical patients, and no trial has specifically targeted 
patients undergoing urgent surgery for obstructive bowel 
disease or gastrointestinal perforation.26–30Patients sched-
uled for urgent gastrointestinal surgery are often fluid 
deranged and preseptic at hospital admission, thus devi-
ating markedly from the patients scheduled for planned 
surgery, and accordingly the mortality and complication 
rates are pronounced.6 31 Studies of care bundles in emer-
gency gastrointestinal surgery and meta-analysis suggest 
that high-risk surgical patients benefit from GDT opti-
misation.32–34 The results has led to a widespread use of 
GDT algorithms within urgent gastrointestinal surgery. In 
opposition, a Cochrane review and a recent meta-analysis 
found no evidence to support this general implementa-
tion.35 36
The GAS-ART study is designed in accordance with a 
firm scientific structure and holds several strengths. The 
computer-generated block randomisation is blinded for 
all investigators, even the project leader. Furthermore, the 
units of Good Clinical Practice audits all patients enrolled 
in the trial and a list of all potential study patients, all 
together minimising the chance of allocation bias. The 
patient group is easily identified in daily clinical prac-
tice using standard radiological actions for the diagnosis 
combined with limited exclusion criteria favouring consec-
utivity of patient enrolment and lessening the chance 
of selection bias. The treatment in both the STD group 
and the GDT group was taught thoroughly to a selected 
group of trial physicians, responsible for the execution of 
the trial at each hospital. Additionally, continuously indi-
vidual and formal teaching by one project leader secured 
unified implementation of both treatment regimens to 
lower performance bias. The primary outcome is clear, 
patient relevant and per-protocol defined consisting of 
six severe complications and death, and two previously 
randomised clinical trials emphasises their applica-
bility.8 37 The primary outcome markers demand medical 
or surgical treatment and will without exception be found 
in the patient’s records. Therefore, we assume no missing 
data related to the primary outcome measures. Addition-
ally, we plan a blinded assessment of the primary outcome 
to reduce detection bias. Data on fluid administration 
during surgery and at the postoperative care unit is 
routinely registered and we expect few missing data. Like-
wise, the secondary outcomes of minor complications call 
for treatment and few missing data are expected. In addi-
tion, the time periods of interest are all easily found in the 
patient journal.
The complexity of the study set-up, however, holds 
weaknesses that need to be addressed. The very nature 
of urgent surgery might impair enrolment of patients in 
the GAS-ART trial. First, operation should be performed 
as fast as possible, giving little time for information of 
the patient, little time for reflection and thus little time 
for informed consent. Second, the treating physicians 
and nurses focus on fast, often life-saving, treatment and 
stabilisation of the patient, which might compromise the 
time for study-related chores and limit patient enrolment. 
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Third, limiting patient enrolment to selected anaesthe-
tists might be challenging because of working shifts. 
Blinding of investigators and patients was not doable 
under the given circumstances, holding a potential of 
performance bias. Emphasis on treatment optimisation 
might be applied to patients in the GDT group, poten-
tially affecting the outcome not only related to the two 
different fluid regimens. On the other hand, the overall 
training and focus on intraoperative and postoperative 
fluid optimisation might enhance the general treatment 
and unify the care in the STD group and GDT group, thus 
eliminating a hypothetical positive effect of either fluid 
regimen. Finally, the use of a composite outcome holds a 
defiance. The most essential shortcoming of a composite 
outcome is the interpretation of the results. The differ-
ence between death and a severe complication is infinite 
in most situations, but not possible to distinguish in the 
result. However, the outcome parameters in the present 
trial will be reported both separately and as an entity.
The choice of intervention fluids needs to be addressed. 
GDT optimisation is usually based on consecutive infu-
sion of hydroxyethyl starch entities. However, two recent 
studies showed increased need for renal replacement 
therapy and death using hydroxyethyl starch for fluid 
resuscitation in patients admitted at the intensive care 
unit. In addition, a Cochrane review questions the use 
of hydroxyethyl starch in randomised trials.38–40 Use of 
crystalloids for GDT optimizations results in increased 
amounts of total intravenous fluid infusion.41 The exces-
sive infusion of chloride-containing fluids might cause 
hyperchloraemia which has been directly associated with 
increased 30-day mortality and length of hospital stay.42 
With an aim to avoid excessive fluid administration and 
due to the disputes about hydroxyethyl starch, we chose 
to use albumin for GDT optimisation in the GDT group. 
Additionally, the treatment algorithm in the STD group 
includes albumin for resuscitation and hinders a poten-
tial treatment bias.
The GAS-ART trial provides strong imperative results 
with a markedly clinical potential. Urgent gastrointestinal 
surgery is common and optimisation of the perioperative 
fluid regimens holds the potential to reduce postopera-
tive death, complications and readmissions.
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